½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1396543

¼¼°èÀÇ ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀå : À¯Çüº°, ¿ëµµº°, ¸ðµåº°, »ç¿ëº° ¿¹Ãø(2023-2032³â)

Ursodeoxycholic Acid Market - By Type (Synthetic, Biological), Application (Gall Stones, Primary Biliary Cholangitis), Mode (In-house, Contract Manufacturing), Use (Human, Veterinary), Global Forecast, 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 172 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê(Ursodeoxycholic Acid) ½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2032³â¿¡ °ÉÃÄ CAGR 10.1%·Î ÃßÀÌÇϸç È®´ë µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. È¿°úÀûÀÎ ´ãÁó»ê ±â¹Ý Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇÇבּ¸¿Í Áø´ÜÀÇ Áøº¸¿¡ Èû¾²°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ Áøº¸°¡ °£ Àå¾ÖÀÇ ÀÌÇØ¿Í Ä¡·á¸¦ °­È­ÇÔ¿¡ µû¶ó, ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê(ÀϹÝÀûÀ¸·Î ¿ì¸£¼Òµ¥¿Ã·Î ¾Ë·ÁÁø)Àº ¸Å¿ì Áß¿äÇÑ Ä¡·á ¿É¼ÇÀ¸·Î ÁÖ¸ñ¹Þ°Ô µË´Ï´Ù. ´ãÁó»ê °ü·Ã Áúȯ¿¡ ´ëÇÑ ¿ì¸£¼Òµ¥¿ÃÀÇ ¿ªÇÒ¿¡ ´ëÇÑ Àνİú ¼ö¿ëÀÌ ³ô¾ÆÁö°í ½ÃÀå ±Ô¸ð¿Í ÀǾàÇ°ÀÇ °ü·Ã¼ºÀÌ °­È­µÊÀ¸·Î½á ±× È¿´ÉÀÌ ÀÎ½ÄµÇ°í ½ÃÀåÀº ÇýÅÃÀ» ¹Þ½À´Ï´Ù.

±â¾÷Àº ¿ì¸£¼Òµ¥¿Á½ÃÄݻ꿡 ´ëÇÑ R&D È°µ¿¿¡ Àû±ØÀûÀ¸·Î Âü¿©ÇÏ¿© ¿ì¸£¼Òµ¥¿Ã ÀǾàÇ°¿¡ ÇÊ¿äÇÑ Çã°¡¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ Àü·«Àû ÃÊÁ¡Àº ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ÀǾàÇ°°ø±Þ È®´ë¸¦ È®º¸ÇÏ°í, È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ°í, ´ãÁó»ê °ü·Ã Áúȯ¿¡ ´ëóÇϱâ À§ÇÑ ÀǾàÇ°ÀÇ Áøº¸¸¦ ÃËÁøÇÔÀ¸·Î½á, ¿ì¸£¼Ò µ¥¿Á½ÃÄÝ»ê»ê¾÷À» °­È­ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â Strides Pharma ScienceÀÇ ¿ÏÀü ÀÚȸ»çÀÎ Strides Pharma GlobalÀº ¹Ì±¹ ½ÄÇ°ÀǾ౹(USFDA)¿¡¼­ ¿ì¸£¼Òµ¥¿Ã ĸ½¶ USP, 300mgÀÇ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù.

¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀå ±Ô¸ð´Â ¸ðµå, ¿ëµµ, Áö¿ª¿¡ µû¶ó ±¸ºÐµË´Ï´Ù.

Á¦¾à ¾÷°è°¡ »ý»ê °øÁ¤ÀÇ ÇÕ¸®È­¿Í ºñ¿ë È¿°ú¸¦ º¸ÀåÇϱâ À§ÇØ ¾Æ¿ô¼Ò½Ì¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀÌ°í ÀÖ´Â °ÍÀÌ ¹è°æ¿¡ ÀÖÀ¸¸ç, 2032³â±îÁö´Â ¼öŹ Á¦Á¶ ºÐ¾ß°¡ Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¼öŹ Á¦Á¶´Â À¯¿¬¼º°ú Àü¹® Áö½ÄÀ» Á¦°øÇÏ¿© Á¦¾à ȸ»ç°¡ ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÀÚ¿ø ÃÖÀûÈ­ ¹× »ý»ê ´É·Â °­È­¿¡ ÁßÁ¡À» µÎ¸é ¼öŹ Á¦Á¶ ºÎ¹®Àº ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê °ø±Þ¿¡ ´ëÇÑ ½ÃÀåÀÇ ÁøÈ­ÇÏ´Â ¿ä±¸¸¦ ÃæÁ·½ÃÅ°´Â ¸Å¿ì Áß¿äÇÑ ¼Ö·ç¼ÇÀ¸·Î µÎµå·¯Áú °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

´ã¼®Áõ¿¡ ´ëÇÑ ÀÀ¿ë ºÐ¾ß´Â ÀÌ È­ÇÕ¹°ÀÇ ´ã¼® ¿ëÇØÀÇ È¿´ÉÀ» ÅëÇØ 2032³â±îÁö ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê»ê¾÷ÀÇ Àü¸ÁÀ» Å©°Ô °­È­ÇÏ°í ºñ¿Ü°úÀû ¼±ÅÃÀ» Á¦°øÇÕ´Ï´Ù. ´ã¼® °ü·Ã ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó, ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»êÀº Áß¿äÇÑ Ä¡·á ¼Ö·ç¼ÇÀ¸·Î ºÎ»óÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÇコÄɾî Á¦°ø¾÷ü°¡ º¸¼öÀûÀÎ Á¢±Ù¹ýÀ» ¼±ÅÃÇÏ´Â °Íó·³, ´ã¼® Àû¿ë ºÎ¹®Àº È¿°úÀûÀÌ°í ÃÖ¼Ò Ä§½À Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ºÎÀÀÇÏ´Â ½ÃÀå¿¡¼­ ¸Å¿ì Áß¿äÇÑ ±â¿© ¿ä¼Ò°¡ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

À¯·´Àº 2023³âºÎÅÍ 2032³â±îÁö ÇöÀúÇÑ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â °£ ÁúȯÀÇ ÀÌȯÀ² Áõ°¡, °ß°íÇÑ °Ç°­ °ü¸® ÀÎÇÁ¶ó, ¼ÒÈ­±â Áúȯ¿¡ ´ëÇÑ Àû±ØÀûÀÎ ´ëÃ¥ µî ¿äÀÎ ¶§¹®ÀÔ´Ï´Ù. ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»êÀ» ±â¹ÝÀ¸·Î ÇÑ Ä¡·á¿¡ ´ëÇÑ Àνİú äÅà Áõ°¡°¡ ÀÌ Áö¿ªÀÇ À¶¼º¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ÇコÄɾîÀÇ Áøº¸¿Í ȯÀÚ¼ö Áõ°¡·Î À¯·´Àº ½ÃÀå¿¡ Å©°Ô ±â¿©ÇÏ°í ÁøÈ­ÇÏ´Â ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê»ê¾÷ÀÇ Àü¸Á¿¡ Å« Á¸Àç°¨À» ³ªÅ¸³¾ °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê »ê¾÷ ÀλçÀÌÆ®

  • ¾÷°è ¿¡ÄڽýºÅÛ
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
  • °¡°Ý ºÐ¼® : Áö¿ªº°
    • ÆǸŠ°¡°Ý
  • Çõ½Å°ú Áö¼Ó°¡´É¼º
  • ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ ¿äÀÎ
    • ¼ºÀå ÃËÁø ¿äÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè°ú °úÁ¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
    • ICE spa
    • Merck KGaA
    • Daewoong Bio
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·«Àû Àü¸Á ¸ÅÆ®¸¯½º
  • ±â¾÷ Á¡À¯À² ºÐ¼®
    • ¼¼°è
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç
  • »ý»ê´É·Â
  • ÃÖÁ¾ ¼ÒºñÀÚ »óÀ§ 20»ç ¸ñ·Ï ¹× ¿¬¶ôó/¸ÞÀÏ ÁÖ¼Ò

Á¦5Àå ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀå : À¯Çüº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : À¯Çüº°
  • ÇÕ¼º ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê
  • »ý¹°ÇÐÀû ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê

Á¦6Àå ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀå : ¿ëµµº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : ¿ëµµº°
  • ¿ø¹ß¼º ´ãÁó¼º ´ã°ü¿°
  • ´ã¼®Áõ
  • ±âŸ ¿ëµµ

Á¦7Àå ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀå : ¸ðµåº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : ¸ðµåº°
  • ÀÚ»ç Á¦Á¶
  • ¼öŹ Á¦Á¶

Á¦8Àå ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀå : »ç¿ëº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : ¿ëµµº°
  • Àΰ£
  • µ¿¹°¿ë

Á¦9Àå ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀå : Áö¿ªº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • µ¶ÀÏ
    • ¿µ±¹
    • ·¯½Ã¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾Æ ÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • ¸»·¹À̽þÆ
    • ±âŸ ¾Æ½Ã¾Æ ÅÂÆò¾ç
  • ³²¹Ì
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • Merck KGaA
  • Changde Yungang Biotechnology Co. Ltd.
  • Daewoong Bio
  • Osmopharm SA
  • ICE spa
  • Dipharma Francis Srl
  • Tianjin NWS Biotechnology and Medicine Co. Ltd
  • Zhongshan Belling Biotechnology Co. Ltd.
  • Axplora
  • Anant Pharmaceuticals Pvt Ltd
  • IOL Chemicals and Pharmaceuticals
  • Glenmark Pharmaceuticals
  • Cerata Pharmaceuticals
  • Kimia Biosciences Ltd
LYJ 23.12.26

Global Ursodeoxycholic Acid Market size will expand at a 10.1% CAGR from 2023 to 2032, propelled by advancements in medical research and diagnostics coupled with a growing demand for effective bile acid-based treatments. As these advancements enhance the understanding and treatment of liver disorders, ursodeoxycholic acid, commonly known as ursodiol, will stand out as a pivotal therapeutic option. Recognized for its efficacy, the market benefits from increasing awareness and acceptance of Ursodiol's role in addressing bile acid-related disorders, bolstering its market size and pharmaceutical relevance.

Companies are actively involved in research and development activities associated with ursodeoxycholic acid, obtaining necessary permissions for ursodiol medications. This strategic focus reinforces the ursodeoxycholic acid industry by ensuring an expanded supply of ursodiol medicines, meeting the growing demand for effective treatments, and fostering pharmaceutical advancements in addressing bile acid-related disorders. For instance, in 2021, Strides Pharma Global, a fully owned subsidiary of Strides Pharma Science, secured approval from the United States Food and Drug Administration (USFDA) for Ursodiol Capsules USP, 300 mg.

The ursodeoxycholic acid market size is segmented based on mode, application, and region.

The contract manufacturing segment will capture a substantial revenue share through 2032, driven by the pharmaceutical industry's increasing reliance on outsourcing to streamline production processes and ensure cost-effectiveness. Contract manufacturing offers flexibility and expertise, enabling pharmaceutical companies to meet the growing demand for ursodeoxycholic acid. With a focus on optimizing resources and enhancing production capabilities, the contract manufacturing segment will stand out as a pivotal solution in satisfying the market's evolving needs for ursodeoxycholic acid supply.

The gallstones application segment will significantly strengthen the ursodeoxycholic acid industry outlook through 2032 due to the compound's efficacy in dissolving gallstones, offering a non-surgical alternative. With an increasing prevalence of gallstone-related conditions, ursodeoxycholic acid will emerge as a key therapeutic solution. As healthcare providers opt for conservative approaches, the gallstones application segment will become a pivotal contributor to the market, catering to the rising demand for effective and minimally invasive treatment options.

Europe will register a notable CAGR from 2023 to 2032, attributed to factors such as the region's increasing incidence of liver disorders, a robust healthcare infrastructure, and proactive measures to address gastrointestinal diseases. Growing awareness and adoption of ursodeoxycholic acid-based treatments contribute to the region's prominence. With a combination of healthcare advancements and a rising patient population, Europe will emerge as a significant contributor to the market, ensuring a substantial presence in the evolving ursodeoxycholic acid industry landscape.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market definition & scope
  • 1.2 Base estimates & calculations
  • 1.3 Forecast parameters
  • 1.4 COVID-19 impact analysis at global level
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Global ursodeoxycholic acid industry 360 degree synopsis, 2018 - 2032
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Type trends
    • 2.1.4 Application trends
    • 2.1.5 Mode trends
    • 2.1.6 Use trends

Chapter 3 Ursodeoxycholic Acid Industry Insights

  • 3.1 Industry ecosystem
  • 3.2 COVID-19 impact analysis
  • 3.3 Regulatory landscape
    • 3.3.1 U.S.
    • 3.3.2 Europe
  • 3.4 Pricing analysis, by region
    • 3.4.1 Selling price in USD per kg
  • 3.5 Innovation & sustainability
  • 3.6 Industry impact forces
    • 3.6.1 Growth drivers
      • 3.6.1.1 Rising prevalence of liver diseases and gallstones
      • 3.6.1.2 Growing pharmaceutical industry
      • 3.6.1.3 Increasing research and development related to ursodeoxycholic acid
    • 3.6.2 Industry pitfalls & challenges
      • 3.6.2.1 Side effects of Ursodeoxycholic acid
  • 3.7 Growth potential analysis
    • 3.7.1 By type
    • 3.7.2 By application
    • 3.7.3 By mode
    • 3.7.4 By use
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
    • 4.1.1 ICE s.p.a.
    • 4.1.2 Merck KGaA
    • 4.1.3 Daewoong Bio
  • 4.2 Competitive positioning matrix, 2022
  • 4.3 Strategic outlook matrix
  • 4.4 Company share analysis, 2022
    • 4.4.1 Global
    • 4.4.2 North America
    • 4.4.3 Europe
    • 4.4.4 Asia Pacific
  • 4.5 Production capacity
  • 4.6 List of top 20 end consumers with contact details/email id

Chapter 5 Ursodeoxycholic Acid Market, By Service Type, 2018 - 2032 (USD Million)

  • 5.1 Key trends, by type
  • 5.2 Synthetic ursodeoxycholic acid
  • 5.3 Biological ursodeoxycholic acid

Chapter 6 Ursodeoxycholic Acid Market, By Application, 2018 - 2032 (USD Million)

  • 6.1 Key trends, by application
  • 6.2 Primary biliary cholangitis
  • 6.3 Gallstones
  • 6.4 Other applications

Chapter 7 Ursodeoxycholic Acid Market, By Mode, 2018 - 2032 (USD Million)

  • 7.1 Key trends, by mode
  • 7.2 In-house manufacturing
  • 7.3 Contract manufacturing

Chapter 8 Ursodeoxycholic Acid Market, By Use, 2018 - 2032 (USD Million)

  • 8.1 Key trends, by use
  • 8.2 Human
  • 8.3 Veterinary

Chapter 9 Ursodeoxycholic Acid Market, By Region, 2018 - 2032 (USD Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 France
    • 9.3.2 Italy
    • 9.3.3 Germany
    • 9.3.4 UK
    • 9.3.5 Russia
    • 9.3.6 Spain
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 South Korea
    • 9.4.5 Australia
    • 9.4.6 Malaysia
    • 9.4.7 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 MEA
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of MEA

Chapter 10 Company Profiles

  • 10.1 Merck KGaA
  • 10.2 Changde Yungang Biotechnology Co. Ltd.
  • 10.3 Daewoong Bio
  • 10.4 Osmopharm SA
  • 10.5 ICE s.p.a
  • 10.6 Dipharma Francis S.r.l.
  • 10.7 Tianjin NWS Biotechnology and Medicine Co. Ltd
  • 10.8 Zhongshan Belling Biotechnology Co. Ltd.
  • 10.9 Axplora
  • 10.10 Anant Pharmaceuticals Pvt Ltd
  • 10.11 IOL Chemicals and Pharmaceuticals
  • 10.12 Glenmark Pharmaceuticals
  • 10.13 Cerata Pharmaceuticals
  • 10.14 Kimia Biosciences Ltd
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦